Abstract
Overview
Introduction
Datamonitor expects few new products to emerge from a week pipeline for both
acute and chronic heart failure. Sales in the seven major markets will be
modest with all the new drugs being add-on therapies to current standard
regimes. Significant unmet patients needs will remain in both acute and
chronic heart failure.
Scope
- Comprehensive analysis of the current acute and chronic heart failure
pipeline detailing the broad of developmental classes.
- A detailed clinical and commercial assessment of all key emerging
therapies.
- Epidemiological based sales forecasts for key late-stage developmental
heart failure agents in the seven major markets to 2016.
Highlights
The heart failure market is relatively stable, with few drugs being launched
in the past five years and many of those launched having significant safety or
commercial viability issues.
It is also a market with high unmet need waiting to be addressed. Patients
with heart failure have a poor prognosis with half of all patients diagnosed
with severe heart failure dying within four years.
The R&D pipeline for heart failure is a Phase II-heavy, diverse range of novel
agents, with 50% all of candidates being in Phase II trials.
Reasons to Purchase
- Quantify the future drugs in the acute and chronic heart failure market.
- Identify licensing opportunities based on company portfolio and market
needs.
- Assess the remaining market opportunity, where established therapies and
other developmental compounds fail to address key unmet clinical needs.
View Cart
